OWH signs patent agreement with Eisai for pro-drug technology
OWH will leverage the technology to progress development of iOWH032, to treat acute secretory diarrhea. The original pro-drug technology was developed at the University of Kansas and the
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
Codexis Pharmaceuticals senior vice president Peter Seufer-Wasserthal said the Codexis technology has delivered solid results including the reduction in production costs for boceprevir. Codexis employed its proprietary CodeEvolver
AggregateSpend360 will support local, country-specific and global transparency and reporting requirements. The service, available in Software as a Service (SaaS) and licensed models, collects all necessary compliance data